

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
BUN/Creatinine Ratio	12			8 - 19	
Sodium, Serum	141		mmol/L	134 - 144	01
Potassium, Serum	4.3		mmol/L	3.5 - 5.2	01
Chloride, Serum	101		mmol/L	96 - 106	01
Carbon Dioxide, Total	23		mmol/L	18 - 29	01
Calcium, Serum	9.2		mg/dL	8.7 - 10.2	01
Protein, Total, Serum	6.9		g/dL	6.0 - 8.5	01
Albumin, Serum	4.2		g/dL	3.5 - 5.5	01
Globulin, Total	2.7		g/dL	1.5 - 4.5	
A/G Ratio	1.6			1.1 - 2.5	
Bilirubin, Total	0.4		mg/dL	0.0 - 1.2	01
Alkaline Phosphatase, S	66		IU/L	39 - 117	01
AST (SGOT)	26		IU/L	0 - 40	01
ALT (SGPT)	21		IU/L	0 - 44	01

Lipid Panel w/ Chol/HDL Ratio

Cholesterol, Total	143		mg/dL	100 - 199	01
Triglycerides	47		mg/dL	0 - 149	01
HDL Cholesterol	43		mg/dL	>39	01
VLDL Cholesterol Calc	9		mg/dL	5 - 40	
LDL Cholesterol Calc	91		mg/dL	0 - 99	
T. Chol/HDL Ratio	3.3		ratio units	0.0 - 5.0	
Please Note:					01

T. Chol/HDL Ratio

	Men	Women
1/2 Avg.Risk	3.4	3.3
Avg.Risk	5.0	4.4
2X Avg.Risk	9.6	7.1
3X Avg.Risk	23.4	11.0

Testosterone, Free and Total

Testosterone, Serum	779		ng/dL	348 - 1197	01
Comment:					
Adult male reference interval is based on a population of lean males up to 40 years old.					
Free Testosterone(Direct)	18.2		pg/mL	8.7 - 25.1	02

DHEA-Sulfate	161.9		ug/dL	138.5 - 475.2	01
---------------------	-------	--	-------	---------------	----

TSH	1.840		uIU/mL	0.450 - 4.500	01
------------	-------	--	--------	---------------	----

Prostate-Specific Ag, Serum

Prostate Specific Ag, Serum	0.7		ng/mL	0.0 - 4.0	01
Roche ECLIA methodology.					
According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical					

Ordered Items

CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel w/ Chol/HDL Ratio; Testosterone, Free and Total; DHEA-Sulfate; TSH; Prostate-Specific Ag, Serum; Vitamin D, 25-Hydroxy; Estradiol, Sensitive; Progesterone; Ferritin, Serum; Venipuncture; Cardiovascular Report

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CBC With Differential/Platelet					
WBC	6.1		x10E3/uL	3.4 - 10.8	01
RBC	6.66	High	x10E6/uL	4.14 - 5.80	01
Hemoglobin	14.8		g/dL	12.6 - 17.7	01
Hematocrit	46.4		%	37.5 - 51.0	01
MCV	70	Low	fL	79 - 97	01
MCH	22.2	Low	pg	26.6 - 33.0	01
MCHC	31.9		g/dL	31.5 - 35.7	01
RDW	14.6		%	12.3 - 15.4	01
Platelets	256		x10E3/uL	150 - 379	01
Neutrophils	56		%		01
Lymphs	33		%		01
Monocytes	7		%		01
Eos	4		%		01
Basos	0		%		01
Neutrophils (Absolute)	3.4		x10E3/uL	1.4 - 7.0	01
Lymphs (Absolute)	2.0		x10E3/uL	0.7 - 3.1	01
Monocytes (Absolute)	0.4		x10E3/uL	0.1 - 0.9	01
Eos (Absolute)	0.3		x10E3/uL	0.0 - 0.4	01
Baso (Absolute)	0.0		x10E3/uL	0.0 - 0.2	01
Immature Granulocytes	0		%		01
Immature Grans (Abs)	0.0		x10E3/uL	0.0 - 0.1	01
Comp. Metabolic Panel (14)					
Glucose, Serum	96		mg/dL	65 - 99	01
BUN	13		mg/dL	6 - 20	01
Creatinine, Serum	1.10		mg/dL	0.76 - 1.27	01
eGFR If NonAfricn Am	90		mL/min/1.73	>59	
eGFR If Africn Am	104		mL/min/1.73	>59	

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.					
Vitamin D, 25-Hydroxy	74.9		ng/mL	30.0 - 100.0	01
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.					
Estradiol, Sensitive	54.8	High	pg/mL	8.0 - 35.0	02
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration. Methodology: Liquid chromatography tandem mass spectrometry(LC/MS/MS)					
Progesterone	0.1		ng/mL	0.0 - 0.1	01
Ferritin, Serum	49		ng/mL	30 - 400	01
Cardiovascular Report					
Interpretation	Note				03
Supplement report is available.					
PDF Image	.				03